

Variables:	Relative Risk of death (95% CI)	P-value	Relative Risk of TRM (95% CI)	P-value
Patient age, yrs		0.0087 ^d		0.04 ^d
31-40 vs. ≤ 30	1.21 (0.88-1.65)	0.25	1.17 (0.83-1.63)	0.37
41-50 vs. ≤ 30	1.21 (0.88-1.67)	0.24	1.16 (0.83-1.63)	0.38
> 50 vs. ≤ 30	1.79 (1.28-2.51)	0.0008	1.72 (1.18-2.49)	0.0044
Patient sex				
Male vs. Female	0.90 (0.72-1.14)	0.40 ^b	1.00 (0.78-1.28)	0.99 ^b
Patient race				
Non-white vs. White	1.07 (0.82-1.41)	0.60 ^b	1.11 (0.83-1.48)	0.48 ^b
Karnofsky performance status		0.35 ^c		0.24 ^c
> 80 vs. ≤ 80	0.78 (0.54-1.11)	0.17	0.76 (0.52-1.12)	0.16
Unknown vs. ≤ 80	0.90 (0.48-1.71)	0.76	1.04 (0.54-1.99)	0.92
Time from diagnosis to HCT, mos				
> 12 vs. ≤ 12	1.52 (1.21-1.92)	0.0004 ^b	1.64 (1.28-2.11)	<0.0001 ^b
Donor type				
Unrelated vs. Matched Sibling	1.66 (1.30-2.13)	<0.0001 ^b	1.81 (1.38-2.37)	<0.0001 ^b
Sex match, Donor/Recipient		0.072 ^d		0.21 ^d
Male/Female vs. Male/Male	1.15 (0.85-1.57)	0.37	1.24 (0.89-1.73)	0.20
Female/Male vs. Male/Male	1.37 (1.02-1.85)	0.039	1.35 (0.97-1.88)	0.075
Female/Female vs. Male/Male	0.89 (0.63-1.25)	0.49	0.99 (0.69-1.42)	0.94
CMV status, Donor/Recipient		0.088 ^e		0.04 ^e
+/- vs. +/+	1.38 (0.94-2.04)	0.10	1.55 (1.03-2.35)	0.037
-/+ vs. +/+	1.43 (1.03-1.98)	0.033	1.57 (1.10-2.23)	0.012
-/- vs. +/+	1.05 (0.77-1.43)	0.75	1.10 (0.78-1.53)	0.60
Unknown vs. +/+	0.89 (0.54-1.45)	0.63	1.00 (0.59-1.68)	0.99
HLA match grade		<0.0001 ^e		<0.0001 ^e
Well matched vs. Matched sibling	1.32 (0.97-1.79)	0.078	1.35 (0.96-1.90)	0.080
Partially matched vs. Matched sibling	1.76 (1.28-2.41)	0.0005	1.91 (1.36-2.67)	0.0002
Mismatched vs. Matched sibling	2.53 (1.77-3.60)	<0.0001	2.86 (1.97-4.15)	<0.0001
Unknown vs. Matched sibling	1.69 (0.96-2.97)	0.068	1.91 (1.04-3.51)	0.038

Conditioning regimen				
Non-myeloablative vs. myeloablative	1.03 (0.73-1.44)	0.87 ^b	0.96 (0.65-1.44)	0.85 ^b
Graft source				
Peripheral blood vs. bone marrow	1.12 (0.87-1.42)	0.38 ^b	1.03 (0.79-1.34)	0.84 ^b
Year of transplant				
2001-2002 vs. 1999-2000	0.84 (0.63-1.11)	0.22	0.83 (0.61-1.13)	0.22
2003-2004 vs. 1999-2000	0.82 (0.59-1.13)	0.21	0.83 (0.59-1.17)	0.28
GVHD prophylaxis regimen				
Tacrolimus + Methotrexate +/- Others vs. TCD	0.72 (0.44-1.16)	0.17	0.65 (0.39-1.08)	0.095
Tacrolimus +/- Others vs. TCD	1.08 (0.51-2.31)	0.84	0.97 (0.40-2.37)	0.94
Cyclosporine + Methotrexate +/- Others vs. TCD	0.64 (0.42-0.96)	0.033	0.57 (0.37-0.88)	0.010
Cyclosporine +/- Others vs. TCD	0.75 (0.45-1.25)	0.27	0.67 (0.39-1.18)	0.17
Imatinib before HCT				
Imatinib vs. No Imatinib	1.32 (0.97-1.79)	0.079 ^b	1.31 (0.94-1.82)	0.12 ^b

Abbreviations: TRM = treatment-related mortality; CI = confidence interval; TCD = T cell depletion; HCT = hematopoietic cell transplantation

^a Reference group

^b One degree of freedom

^c Two degrees of freedom

^d Three degrees of freedom

^e Four degrees of freedom